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While  bradykinin  has  been  identiﬁed  in the  skin  secretions  from  several  species  of  amphibian,  bradykinin-
related  peptides  (BRPs)  are  more  common  constituents.  These  peptides  display  a  plethora  of  primary
structural  variations  from  the  type  peptide  which  include  single  or multiple  amino  acid  substitutions,
N-  and/or  C-terminal  extensions  and  post-translational  modiﬁcations  such  as  proline  hydroxylation  and
tyrosine  sulfation.  Such  modiﬁed  peptides  have  been  reported  in species  from  many  families,  including
Bombinatoridae,  Hylidae  and  Ranidae.  The  spectrum  of  these  peptides  in  a  given  species  is thought  to
be  reﬂective  of  its predator  proﬁle  from  different  vertebrate  taxa.  Here  we  report  the  isolation  of  BRPs
and  parallel  molecular  cloning  of their  respective  biosynthetic  precursor-encoding  cDNAs  from  the skinkin
eptides
olecular cloning
radykinin
mooth muscle
secretions  of the  Mexican  leaf  frog  (Pachymedusa  dacnicolor),  the Central  American  red-eyed  leaf frog
(Agalychnis  callidryas)  and  the  South  American  orange-legged  leaf  frog  (Phyllomedusa  hypochondrialis).
Additionally,  the eight  different  BRPs  identiﬁed  were  chemically  synthesized  and screened  for  bioactiv-
ity  using  four  different  mammalian  smooth  muscle  preparations  and  their  effects  and  rank  potencies
were  found  to be  radically  different  in these  with  some  acting  preferentially  through  bradykinin  B1-type
receptors  and  others  through  B2-type  receptors.. Introduction
The discovery of bradykinin (BK) has its roots in venom research
oing back as far as 1949 when Rocha et al. incubated trypsin
r whole snake venom with plasma proteins [18]. The resultant
igests were found to stimulate certain types of smooth muscle
reparations, including the uterus and ileum of guinea pigs and
 The nucleotide sequences of clones encoding respective BRP precursors from
he  skin secretions of the Mexican leaf frog (Pachymedusa dacnicolor), the Cen-
ral American red-eyed leaf frog (Agalychnis callidryas) and the South American
range-legged leaf frog (Phyllomedusa hypochondrialis), have been deposited in the
MBL Nucleotide Sequence Database under the accession codes HE967329 through
E967331.
∗ Corresponding authors at: Natural Drug Discovery Group, School of Pharmacy,
ueen’s University, Belfast BT9 7BL, Northern Ireland, UK. Tel.: +44 02890 972200;
ax: +44 02890 247794.
E-mail addresses: r.li@qub.ac.uk (R. Li), l.wang@qub.ac.uk (L. Wang).
1 These authors contributed equally to this work.
196-9781/$ – see front matter © 2013 Elsevier Inc. All rights reserved.
ttp://dx.doi.org/10.1016/j.peptides.2013.12.013© 2013  Elsevier  Inc.  All  rights  reserved.
rats and the intestine of rabbits. Moreover, when the digest was
injected into the veins of rabbits and cats, a fall in arterial blood
pressure was  observed. The active agent (BK) was thus considered
to be a general mammalian hypotensive and myotropic agent that
could be used in the treatment of hypertension [19].
BK is biosynthesized in the liver as a relatively small domain
within the structures of higher molecular weight protein pre-
cursors (the kininogens). The levels of BK in plasma and tissue
ﬂuids under normal physiological conditions are low and these
are increased through the actions of certain proteases (kallikreins)
on kininogens at sites of trauma, inﬂammation or infection [1,17].
However, the biosynthesis of BK and BK-related peptides (BRPs)
in the skins of various amphibians, follows a quite different path-
way to that observed in the plasma and tissues of mammals (the
kallikrein-kinin system) [1,9,17].Bradykinin and BRPs are encoded, like the majority of other
groups of amphibian skin peptides, by precursor proteins that
have a highly ordered and highly conserved structure consisting
of an N-terminal signal peptide domain, followed by an acidic
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mino acid residue-rich (spacer) domain and terminating in a
ypervariable mature peptide (BRP)-encoding domain [3–8,20,22].
any amphibian skin BRP-encoding precursors, while having the
-terminal signal peptide domain, have multiple tandem-repeats
f acidic spacer peptide/BRP-encoding domains, the latter either
ncoding identical BRPs or a variety of such [3–8,20,22].
The BRPs of amphibian skin occur in an astonishing diver-
ity of primary structures in addition to the original nonapeptide
3–8,20,22]. This structural diversity includes single or multiple
mino acid substitutions within the core nonapeptide sequence,
xtensions of various lengths at the N- and/or C-terminals, and one
r more post-translational modiﬁcations which include hydroxyl-
tion of prolyl residues and/or sulfation of tyrosyl residues [7,8].
RPs are of widespread distribution in amphibian skin, occur-
ing in representative species of the major families, Ranidae and
ylidae and the minor families, Bombinatoridae and Ascaphidae
3–10,20,22].
Neotropical hylid frogs of the sub-family, Phyllomedusinae,
ave long been considered to produce among the most chemically
omplex and biologically potent skin secretions of any amphib-
an taxon [12]. Thus, in this report, BRPs have been studied in
he skins of three species of phyllomedusine frogs representative
f three genera within the sub-family, namely, Pachymedusa dac-
icolor (Mexico), Agalychnis callidryas (most of Central America)
nd Phyllomedusa hypochondrialis (most of Northern South Amer-
ca). A functional genomic approach was employed that consisted
f “shotgun” molecular cloning of skin BRP precursor-encoding
DNAs, prediction of mature BRP sequences from these templates,
ocalization of the predicted peptides in HPLC fractions of skin
ecretion and conﬁrmation of their structures using mass spectro-
etric techniques, their solid-phase chemical synthesis and ﬁnally,
heir pharmacological evaluation using four different mammalian
mooth muscle preparations.
Using this approach, eight different BRPs were identiﬁed
esulting from differential processing of respective precursors
nd post-translational modiﬁcation of products. Pharmacologi-
al evaluation of these BRPs in the mammalian smooth muscle
reparations revealed substantial differences in their potencies and
arget receptors in a tissue-dependent manner.
. Materials and methods
.1. Specimen biodata and secretion harvesting
Specimens of Pachymedusa dacnicolor,  Agalychnis callidryas and
hyllomedusa hypochondrialis (n = 3 in each case) were obtained
rom commercial sources and were kept for a period of 4 months
rior to secretion harvesting. They were maintained in our purpose-
esigned amphibian facility at 18–25 ◦C under a 12/12-h light/dark
ycle and fed multivitamin-loaded crickets three times per week.
efensive skin secretions were obtained from each specimen by
ither gently squeezing the paired parotoid and tibial glands or by
assaging the dorsal skin with a latex-gloved ﬁnger. Secretions
ere then washed from the skin using deionized water, snap-
rozen in liquid nitrogen and lyophilized. Lyophilizates were stored
t −20 ◦C prior to analysis.
.2. “Shotgun” cloning of BRP precursor-encoding cDNAs
Five mg  of lyophilized skin secretion from each species were
eparately dissolved in 1 ml  of cell lysis/mRNA stabilization
olution (Dynal, UK). Polyadenylated mRNA was isolated from
his stabilization solution using magnetic oligo-dT beads as
escribed by the manufacturer (Dynal Biotech, UK) and reverse-
ranscribed. Brieﬂy, the 3′-RACE reactions employed an NUP primer2 (2014) 122–133 123
(supplied with the kit) and a degenerate sense primer
pool (3′-RACE; 5′-CCRVCNGGGTTYASSCCWTTY-3′) (R = A/G,
V = A/C/G, N = A/C/T/G, Y = C/T, S = C/G, W = A/T) that was
complementary to the nucleic acid sequence encoding
the—PPGFSPF—and—PPGFTPF—internal amino acid sequences
of skin bradykinin-like peptide (BRP) precursor transcripts
from other phyllomedusine frog species [7,8]. The products
of 3′-RACE reactions were gel-puriﬁed and cloned using a
pGEM-T vector system (Promega Corp.) and sequenced using
an ABI 3100 automated sequencer. Following acquisition
of these data, a degenerate antisense primer pool (AS1, 5′-
GCTCYTBAGATTAYSGCATSYTACWTT-3′) (B = T/C/G) was designed
to a site in the 3′-untranslated region and was  employed in
5′-RACE reactions. Products were likewise gel-puriﬁed, cloned and
sequenced as described above.
2.3. Identiﬁcation and structural analyses of deduced BRP
homologs
Samples (5 mg)  of lyophilized skin secretion from each species
were separately dissolved in 1 ml  of 0.05/99.95 (v/v) triﬂuo-
roacetic acid (TFA)/water and were clariﬁed of microparticulates
by centrifugation (1500 × g) for 10 min. The clear supernatants
were then each separately pumped directly onto a reverse
phase HPLC column and peptides were eluted using a gradi-
ent formed from 0.05/99.95 (v/v) TFA/water to 0.05/19.95/80.00
(v/v/v) TFA/water/acetonitrile in 80 min  at a ﬂow rate of 1 ml/min.
A Cecil CE4200 Adept (Cambridge, UK) gradient reverse phase
HPLC system, ﬁtted with an analytical column (Phenomenex C-5,
0.46 cm × 25 cm) was employed and fractions were collected auto-
matically at 1 min intervals. Dead volume between column and
fraction collector was minimal (20 l). The molecular masses of
peptides in each chromatographic fraction were determined by
using matrix-assisted, laser desorption/ionization, time-of-ﬂight
mass spectrometry (MALDI-TOF MS)  on a linear time-of-ﬂight Voy-
ager DE mass spectrometer (Perseptive Biosystems, MA,  USA) in
positive detection mode using -cyano-4-hydroxycinnamic acid as
the matrix. Internal mass calibration of the instrument with known
standards established the accuracy of mass determination as ±0.1%.
The peptides with masses coincident with those of BRPs deduced
from cloned precursor cDNAs, were each subjected to primary
structural analyses by MS/MS  fragmentation sequencing using an
LCQ Fleet electrospray ion-trap mass spectrometer (Thermo Fisher
Scientiﬁc, San Jose, CA, USA).
2.4. Solid-phase peptide synthesis
Replicates of the eight different BRPs identiﬁed were chemically
synthesized by solid-phase Fmoc chemistry using a PS3 automated
solid-phase synthesizer (Protein Technologies, Inc., AZ, USA). Fol-
lowing cleavage from the resin and subsequent deprotection of
side-chains, each synthetic peptide was  analyzed by both reverse
phase HPLC and MALDI-TOF mass spectrometry to establish both
degree of purity and authenticity of structure. For pharmacolog-
ical experiments, standardization of the synthetic peptide was
achieved by acid hydrolysis of a known gravimetric quantity of
lyophilizate followed by amino acid analysis using an Applied
Biosystems PTH-amino acid analyzer.
2.5. Smooth muscle pharmacologyAdult male Wistar rats, weighing 200–250 g, were killed by
asphyxiation with CO2 followed by cervical dislocation in accor-
dance with institutional animal experimentation ethics and UK
animal research guidelines.
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For tail artery smooth muscle preparations, the animals were
aid on their dorsal surfaces, followed by removal of the tail skin.
he arterial vascular bed was identiﬁed and moistened with Krebs’
olution (118 mM NaCl, 4.7 mM KCl, 25 mM NaHCO3, 1.15 mM
aH2PO4, 2.5 mM CaCl2, 1.1 mM MgCl2 and 5.6 mM glucose). The
embrane and the connective tissue beneath the main artery
ere carefully removed. The proximal region of the tail artery was
xcised and immediately placed in ice-cold Kreb’s solution. Two
m-wide rings of artery were cut and mounted on a transducer
rior to placing in 2 ml  organ baths containing Kreb’s solution ﬂow-
ng through at 2 ml/min and maintained at 37 ◦C with constant
ubbling of carbogen gas mixture (95% O2/5%CO2). Muscle rings
ere equilibrated for 1 h before experimental procedures were ini-
iated. Each synthetic peptide solution, ranging in concentration
rom 10−11 to 10−5 M,  was made using Kreb’s solution and these
ere used in the construction of dose–response curves. Each was
dded to the arterial muscle strips, which were placed under 0.5 g
f tension, in increasing concentrations with 5 min washes and
 min  equilibration periods between each dose. Each concentra-
ion of individual peptides was applied to a minimum of six muscle
trips. Changes in tension of the artery muscle strips were recorded
nd ampliﬁed through pressure transducers connected to a Pow-
rLab System (AD Instruments Pty Ltd.). Data were analyzed to
btain the mean and standard error of responses by Student’s t-
est and dose–response curves were constructed using a “best-ﬁt”
lgorithm through the data analysis package provided.
For urinary bladder smooth muscle preparations, the exposed
rinary bladder was removed from each rat, emptied of urine
nd placed in ice-cold Kreb’s solution, equilibrated with 95% O2,
%CO2. Muscle strips, 2 mm × 10 mm,  were dissected from the blad-
er under a dissection microscope. These were tied at each end
ith a ﬁne silk thread (0.2 mm diameter) with one end subse-
uently attached to a ﬁxed pin and the other to a transducer in
 2 ml  organ bath containing Kreb’s solution at 37 ◦C ﬂowing at
 ml/min with constant bubbling of 95% O2, 5%CO2. The bladder
trips were gradually exposed to increasing tension until 0.5 g was
eached and maintained. The preparations were then exposed to
eptides as described previously and relative changes in tension
ere recorded.
For uterus smooth muscle preparations, female Wistar rats were
sed and treated as described previously for males. Uterine horns
ere removed in their entirety and placed in ice-cold Kreb’s solu-
ion which was vigorously aerated with mixture gas (95% CO2;
% O2). Each uterine horn was halved and individual strips were
ounted in a 2 ml  organ bath, perfused with Krebs’ solution at
7 ◦C for 10 min  with no tension. The uterus strips were grad-
ally exposed to increasing tension until 0.5 g was reached and
aintained. The uterus smooth muscle preparations were exposed
o peptides as described previously and, in contrast to bladder
uscle strips, whose tension changes were recorded, changes
n spontaneous contraction frequencies were recorded for these
reparations.
For ileum smooth muscle preparations, 1-cm thick rings of
istal small intestine were carefully placed onto the pins of a
acLab force transducer, with one acting as a stationary ﬁxed
oint while the second was free, permitting application of ten-
ion to the smooth muscle. The intestinal strips were gradually
xposed to increasing tension until 0.5 g was reached and main-
ained. The intestinal smooth muscle preparations were exposed
o peptides as described previously and relative changes in tension
ere recorded. To examine which BK receptors were targeted in
ach tissue, after dose–response curves for all peptides had been
onstructed in each, peptides at a single maximal dose (10 m)
ere applied to three preparations in the absence or presence of
ither the bradykinin B1 receptor antagonist, desArg-HOE140, or
he bradykinin B2 receptor antagonist, HOE140. Data were recorded2 (2014) 122–133
as percentages of maximal responses in the absence of either recep-
tor antagonist.
3. Results
3.1. Cloning of BRP precursor-encoding cDNAs
A single BRP-encoding cDNA was  consistently cloned from the
skin secretion-derived cDNA library of each species of frog and
each encoded a single copy of a novel bradykinin-related peptide
(Fig. 1A–C). Respective open-reading frames consisted of 61 amino
acid residues containing a putative hydrophobic signal peptide,
an acidic amino acid residue-rich prodomain and a single copy of
(Thr6-BK/RD-11) or (Val1, Thr6-BK/VS-11) coding sequence located
at their C-terminals (Fig. 1A–C). Alignments of both open-reading
frame nucleotide sequences (Fig. 2A) and amino acid sequences
(Fig. 2B), using the AlignX program of the Vector NTI Bioinformat-
ics Suite (Informax), revealed that the BRP-encoding domains were
located at identical positions within respective precursors. All pre-
cursors exhibited a high degree of both nucleotide and primary
structural similarity with sequence heterogeneity being predomi-
nantly localized to their C-terminal regions.
3.2. Isolation and structural characterization of respective BRP
precursor-encoded mature peptides
From cloned cDNAs, several putative BRPs were predicted.
Interestingly, the four BRPs predicted from the cloned skin BRP
precursor-encoding cDNAs of Pachymedusa dacnicolor and Agaly-
chnis callidryas, were identical. The four predicted from the cloned
BRP precursor-encoding cDNA from Phyllomedusa hypochondri-
alis,  were different from these. In predicting putative mature
BRPs from each species, probable processing sites and possi-
ble post-translational modiﬁcation sites, such as hydroxylation
of Pro-3, were assessed based upon previous knowledge of
these from other frog species. In skin secretion fractions from
Pachymedusa dacnicolor and Agalychnis callidryas (Fig. 3A and B),
the four BRPs identiﬁed were identical in structure and were
(Thr6)-BK, (Hyp3-Thr6)-BK, (Thr6)-bradykinyl-VD) (RD-11) and
(Hyp3, Thr6)-bradykinyl-VD (Hyp3-RD-11). In contrast, the four
BRPs identiﬁed in skin secretion fractions from Phyllomedusa
hypochondrialis (Fig. 3C) were Val1-Thr6-BK, Val1-Hyp2-Thr6-
BK, Val1-Thr6-bradykinyl-QS and Val1-Hyp2-Thr6-bradykinyl-QS
(Table 1). The amino acid sequences of each identiﬁed BRP
were established by use of electrospray MS/MS  fragmentation
(Figs. 4 and 5). The results of several bioinformatic analyses of
BRP-encoding domains of respective cloned precursors and of
mature peptides using the National Center for Biotechnological
(NCBI) database, are shown in Fig. 6. Mature BRP-encoding domains
and the location of propeptide convertase processing sites within
respective cDNA-translated precursor proteins (Fig. 6A and C),
were found to be highly conserved within the phyllomedusine frog
species studied to date. Additionally, the common peptide, RD-11,
of A. callidryas and P. dacnicolor,  was found to exhibit signiﬁcant
structural similarity to BRPs reported from frogs from other taxa
(Ascaphus truei and Physalaemus signifer) as well as to BRPs from
then venoms of several species of vespid wasp (Vespa tropica and
Vespa mandarinia) (Fig. 6B).
3.3. Smooth muscle pharmacologyFigs. 7–10 summarize the data (dose–response curves) obtained
with the synthetic replicates of each of the eight skin BRPs iden-
tiﬁed in this study. The results obtained were both complex
and diverse in each smooth muscle preparation. While synthetic
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A)      M  S  F   L  K  K  S   L  F  L   V  L  F   L  G  F   V
1 ATGTCATTCT TGAAGAAGTC  TCTTTTCTTG GTACTTTTCC TCGGATTCG T
TACAGTAAGA ACTTCTTCAG AGAAAAGAAC CATGAAAAGG AGCCTAAGCA
S  F  S   I  C E   E  E  K  R   E  D  E   E  E  E   
51 TTCCTTTTCC ATCTGTGAAG AAGAGAAAAG AGAGGATGAA GAAGAGGAG A
AAGGAAAAGG TAGACACTTC TTCTCTTTTC TCTCCTACTT CTTCTCCTC T
N  E  R  E   E  N  K   E  S  E   E  K  R  N   Q  E  E
101 ATGAGAGAGA GGAAAACAAA GAAAGTGAAG AGAAGAGAAA TCAAGAGGA G
TACTCTCTCT CCTTTTGTTT CTTTCACTTC TCTTCTCTTT AGTTCTCCTC
R  P  P   G  F  T  P   F  R  V   D *
151 AGACCTCCTG GTTTCACTCC TTTTAGAGT T GACTAACTCA TTGAAACAA A
TCTGGAGGAC CAAAGTGAGG AAAATCTCAA CTGATTGAGT AACTTTGTTT
201 AGTAAGATGC GGTAATCTGA AGAGCACAAT TATCGGTAAT TATGCTAAA A
TCATTCTACG CCATTAGACT TCTCGTGTTA ATAGCCATTA ATACGATTTT
251 ACAATAAAGC GTTATAACAA AAAAAAAAAA AAAAAAAA A
TGTTATTTCG CAATATTGTT TTTTTTTTTT TTTTTTTT T
B)      M  S  F   L  K  K  S   L  F  L   V  L  F   L  G  L   V
1 ATGTCATTCT TGAAGAAATC TCTTTTCTTG GTACTTTTCC TTGGATTGGT
TACAGTAAGA ACTTCTTTAG AGAAAAGAAC CATGAAAAGG AACCTAACCA
S  F  S   I  C E   E   E K  R   E  T  E   E  E  E   
51 TTCCTTTTCC ATCTGTGAAG AAGAGAAAAG AGAGACTGAA GAAGAGGAG A
AAGGAAAAGG TAGACACTTC TTCTCTTTTC TCTCTGACTT CTTCTCCTCT
N  E  D  E   M  D  K   E  S  E   E  K  R  E   S  P  E
101 ATGAAGATGA AATGGACAAA GAAAGTGAAG AGAAGAGAGA GTCT CCAGA G
TACTTCTACT TTACCTGTTT CTTTCACTTC TCTTCTCTCT CAGAGGTCTC
R  P  P   G  F  T  P   F  R  V   D *
151 AGACCTCCCG GTTTCACTCC TTTTCGAGTT GATTAACACA TTGAAAAAA A
TCTGGAGGGC CAAAGTGAGG AAAAGCTCAA CTAATTGTGT AACTTTTTTT
201 AGTAACATGC GGTAATCTAA GGAGCACA AT TATAAGTAAT TATGCTAAA A
TCATTGTACG CCATTAGATT CCTCGTGTTA ATATTCATTA ATACGATTTT
251 ACATTAAAAC ATATTTAATG GAAAAAAAAA AAAAAAAAAA AAAAAAAAA A
TGTAATTTTG TATAAATTAC CTTTTTTTTT TTTTTTTTTT TTTTTTTTTT
C)      M  S  I   L  K   K S   L  F  L   V  L  F   L  G  L   V
1 ATGTCTATCT TGAAGAAATC TCTGTTCCTT GTACTTTTCC TCGGATTGG T
TACAGATAGA ACTTCTTTAG AGACAAGGAA CATGAAAAGG AGCCTAACCA
S  F  S   I  C E   E  E  K  R   E  A  E   E  E  E   
51 TTCCTTTTCC ATCTGTGAAG AAGAGAAAAG AGAGGC TGAA GAGGAAGAG A
AAGGAAAAGG TAGACACTTC TTCTCTTTTC TCTCCGACTT CTCCTTCTCT
N  E  D  E   I  E  E   Q  S  E   E  K  K  R   F  E  P
101 ATGAAGACGA AATAGAGGAA CAAAGTGAAG AGAAGAAAAG ATTTGAACC A
TACTTCTGCT TTATCTCCTT GTTTCACTTC TCTTCTTTTC TAAACTTGGT
V  P  P   G F  T  P   F  R  Q    S *
151 GTACCTCCCG GTTTCACACC CTTTCGACAA AGTTAATACA TTAAGAAAA T
CATGGAGGGC CAAAGTGTGG GAAAGCTGTT TCAATTATGT AATTCTTTTA
201 GTAGCATGCC ATAATCTCAA GAGCAGAGTT ATTAAGAATT ATGCTAAAA A
CATCGTACGG TATTAGAGTT CTCGTCTCAA TAATTCTTAA TACGATTTT T
251 AATATTAAAC AATAATAATA TTAAAAAAAA AAAAAAAAAA AAAAAAAAA A
TTATAATTTG TTATTATTAT AATTTTTTTT TTTTTTTTTT TTTTTTTTTT
Fig. 1. Nucleotide and translated open-reading frame amino acid sequences of cloned cDNAs encoding the biosynthetic precursors of skin bradykinins from selected
phyllomedisne frogs. (A) Pachymedusa dacnicolor, (B) Agalychnis callidryas and (C) Phyllomedusa hypochondrialis. Putative signal peptide sequences are double-underlined,
mature peptide sequences are single underlined and stop codons are indicated by asterisks.
Table 1
Identiﬁcation and characterization of skin BRPs in three species of phyllomedusine frogs.
Species Peptide Original
fraction
Mass observed
(Da)
Mass
calculated (Da)
Amino acid sequence
Pachymedusa dacnicolor (Thr6)-bradykinin 35 1073.45 1073.25 RPPGFTPFR (T6-BK)
Pachymedusa dacnicolor (Hyp3, Thr6)-bradykinin 35 1089.70 1089.25 RP-Hyp-GFTPFR (Hyp3, T6)-BK
Pachymedusa dacnicolor Thr6-bradykinyl-VD 38 1287.90 1287.47 RPPGFTPFRVD (RD-11)
Pachymedusa dacnicolor (Hyp3)-bradykinyl-VD 38 1303.55 1303.47 RP-Hyp-GFTPFRVD (Hyp3-RD-11)
Agalychnis callidryas (Thr6)-bradykinin 36 1073.35 1073.25 RPPGFTPFR (T6-BK)
Agalychnis callidryas (Hyp3, Thr6)-bradykinin 36 1089.55 1089.25 RP-Hyp-GFTPFR (Hyp3, T6)-BK
Agalychnis callidryas Thr6-bradykinyl-VD 39 1287.65 1287.47 RPPGFTPFRVD (RD-11)
Agalychnis callidryas (Hyp3)-bradykinyl-VD 39 1303.80 1303.47 RP-Hyp-GFTPFRVD (Hyp3-RD-11)
Phyllomedusa hypochondrialis (Val1, Thr6)-bradykinin 32 1016.50 1016.2 VPPGFTPFR (V1, T6)-BK
Phyllomedusa hypochondrialis (Val1, Hyp2, Thr6)bradykinin 32 1032.65 1032.2 V-Hyp-PGFTPFR (V1, Hyp2, T6)-BK
Phyllomedusa hypochondrialis (Val1, Thr6)bradykinyl-QS 35 1231.95 1231.41 VPPGFTPFRQS (VS-11)
Phyllomedusa hypochondrialis (Val1, Hyp2, Thr6)bradykinyl-QS 35 1247.85 1247.41 V-Hyp-PGFTPFRQS (Hyp2-VS-11)
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Fig. 2. Alignments of skin bradykinin precursor-encoding cDNA nucleotide sequences (A) and open-reading frame amino acid sequences (B) from selected phyllomedusine
frogs.  BK-PD, Pachymedusa dacnicolor,  BK-AC, Agalychnis callidryas and BK-PH, Phyllomedusa hypochondrialis. In (A), identical nucleotides are back-shaded in black and
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eplicates of the four BRPs present in both Pachymedusa dacni-
olor and Agalychnis callidryas skins (RD-11, Hyp3-RD-11, T6-BK
nd (Hyp3, T6)-BK), were found to relax the smooth muscle of
at tail artery (range 3.5 ± 0.3 nM to 56.7 ± 3 nM,  mean ± SE), the
our BRPs from Phyllomedusa hypochondrialis skin (VS-11, Hyp2-
S-11, (V1, T6)-BK and (V1, Hyp2, T6)-BK) were devoid of any
uch activity up to a concentration of 100 M (Fig. 7). Reﬂecting
hese data, the synthetic replicates of the four common BRPs from
achymedusa dacnicolor and Agalychnis callidryas skin, were also
ctive in contracting the smooth muscles of rat urinary bladder
range 895 ± 47 nM to 4.6 ± 0.5 M,  mean ± SE) and uterus (range
.9 ± 0.5 nM–1.2 ± 0.4 M,  mean ± SE) while the four Phyllomedusa
ypochondrialis skin BRPs were likewise ineffective up to a con-
entration of 100 M (Figs. 8 and 9). However, of interest was the
nding that each of the eight synthetic replicates of the skin BRPs
ontracted the smooth muscle of rat ileum (range 205 ± 19 nM to
.7 ± 0.2 M,  mean ± SE) (Fig. 10). The most potent effects observed
or any of the BRPs in a smooth muscle type were for Hyp3-RD-
1 (EC50 = 3.5 ± 0.3 nM)  on arterial smooth muscle and for (Hyp3,
6)-BK (EC50 = 3.9 ± 0.5 nM)  on uterus smooth muscle. Compara-
le EC50 values for BK in these two smooth muscle preparations
ere 170 nM and 6.7 nM,  respectively (data not shown). The results
f selective bradykinin receptor antagonist studies on each of the
mooth muscle preparations, are summarized in Table 2. These
ata present a complex picture of BRP/receptor interaction in eachtical amino acid residues are back-shaded in black, sites of amino acid differences
smooth muscle tissue. In arterial smooth muscle, BK, RD-11 and
Hyp3-RD-11, appear to act via B2 receptors, in urinary bladder,
BK and Hyp3-RD-11 appear to act through B2 receptors, in uterus,
BK, RD-11 and Hyp3-RD-11, appear to act via B2 receptors and in
ileum, BK acts through B2 receptors, RD-11 and Hyp3-RD-11 act
predominantly through B2 receptors but also signiﬁcantly through
B1 receptors with T6-BK, Hyp3, T6-BK, Hyp2-VS-11 and V1, T6-BK
acting predominantly through B1 receptors but also signiﬁcantly
through B2 receptors. V1, Hyp2, T6-BK appears to be quite selective
for B1 receptors.
4. Discussion
Bradykinin (BK) possesses a substantial range of bioactivities
and is found in the circulation and tissues of mammals where it is
generated in its active form from high molecular weight precursor
proteins (kininogens) by the actions of a group of endogenous pro-
teases (kallikreins) [1,17]. Although its actions are varied, among
the most pronounced are those that affect the smooth muscles
found in many organ systems such as the cardiovascular, digestive,
reproductive and excretory [1,17]. The effects can also be highly
species-speciﬁc. Even within a single system, however, the actions
of BK can be quite complex, such that while it can induce vasodila-
tion and increase blood ﬂow through its actions on arterial smooth
muscles, it can, in contrast, induce vasoconstriction and plasma
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nig. 3. Regions of reverse phase HPLC chromatograms of (A) Pachymedusa dacnic
lution positions/retention times of translated cloned cDNA-predicted bradykinin-r
xtravasation in venous smooth muscles [1,17]. These observations
ave been explained through receptor coupling to different second
essenger pathways in different cells and/or to the presence of
ifferent regional proﬁles of receptor subtype expression [1,17].
In mammals, including humans, the primary structure of BK
ppears to be invariant as is the presence of two different subtypes
f BK receptors, designated B1 and B2 [14,15] and both are clas-
ical, seven trans-membrane domain, G-protein-linked receptors
GPCRs) [2,11,14,15]. The B2 receptor is constitutively expressed
y many types of cells, including smooth muscle cells, while the B1
eceptor is inducible and is expressed de novo in various cell types
fter trauma or at sites of chronic inﬂammation [2,11,14,15]. Each
eceptor has different ligand structure/activity requirements with
K activating both but with des-(Arg9)-BK being the preferential
igand for the B1 subtype [2,11,14,15]. Differentiation of receptors
ub-types for discrete peptide ligands usually requires the avail-
bility and utilization of fragments and structural analogs of the
atural ligand [2,11,14,15].) Agalychnis callidryas and (C) Phyllomedusa hypochondrialis skin secretions with
 peptides (BRPs) indicated by numbered arrows.
The skin secretions of amphibians have proven to be the rich-
est source of bradykinin-related peptides (BRPs) and these diverse
analogs of bradykinin provide an unequaled source of naturally
selected ligands with which to pharmacologically probe the struc-
ture/activity requirements of both bradykinin receptor ligands and
the receptors themselves.
In this study, the primary structures of eight different BRPs were
established from three species of phyllomedusine leaf frogs. In two
of the species, Pachymedusa dacnicolor and Agalychnis callidryas,
the four BRPs identiﬁed were of identical primary structure and
were produced by differential processing and chemical modiﬁca-
tion from a single precursor. Those found in the skin secretion of the
third species studied, Phyllomedusa hypochondrialis, were of differ-
ent primary structure but were apparently generated likewise from
a single precursor by similar processing and chemical modiﬁcation
mechanisms.
The pharmacological activities of synthetic replicates of each of
these eight BRPs were assessed using four different mammalian
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(A)
(B)
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2
1 157 .10 79 .05 R 11
2 254 .16 127 .58 P 11 32.57 566 .79 10
3 351 .21 176 .11 P 10 35.52 518 .26 9
4 408.23 204.62 G 938.47 469.74 8
5 555.30 278 .15 F 881 .45 441 .22 7
6 656.35 328.67 T 734.38 367.69 6
7 753 .40 377 .20 P 633 .33 317 .17 5
8 900 .47 450 .73 F 536 .28 268 .64 4
9 10 56.57 528 .79 R 389 .21 195 .11 3
10 11 55.64 578 .32 V 233 .11 117 .06 2
11 D 134 .04 67 .52 1
(D)
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2
1 157 .10 79 .05 R 11
2 254 .16 127 .58 P 11 48.57 574 .79 10
3 367 .20 184 .10 P-
Oxida tion
1051.52 526 .26 9
4 424.23 212.61 G 938.47 469.74 8
5 571 .29 286 .15 F 881 .45 441 .22 7
6 672 .34 336 .67 T 734 .38 367 .69 6
7 769 .39 385 .20 P 633 .33 317 .17 5
8 916 .46 458 .73 F 536 .28 268 .64 4
9 10 72.56 536 .78 R 389 .21 195 .11 3
10 11 71.63 586 .32 V 233 .11 117 .06 2
11 D 134 .04 67 .52 1
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2
1 157.11 79.06 R 9
2 254 .16 127 .58 P 918 .48 459 .75 8
3 351 .21 176 .11 P 821 .43 411 .22 7
4 408 .24 204 .62 G 724 .38 362 .69 6
5 555.30 278.16 F 667.36 334.18 5
6 656.35 328.68 T 520.29 260.65 4
7 753.40 377.21 P 419.24 210.12 3
8 900 .47 450 .74 F 322 .19 161 .60 2
9 R 175.12 88.06 1
(C)
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2
1 157 .11 79 .06 R 11
2 254 .16 127 .58 P 11 48.57 574 .79 10
3 367 .21 184 .11 P-
Oxida tion
1051.52 526 .26 9
4 424.23 212.62 G 938.47 469.74 8
5 571 .30 286 .11 F 881 .45 441 .22 7
6 672 .35 336 .68 T 734 .38 367 .69 6
7 769.40 385.20 P 633.33 317.17 5
8 916.47 458.74 F 536.28 268.64 4
9 10 72.57 536 .79 R 389 .21 195 .11 3
10 1171.64 586.32 V 233.11 117.06 2
11 D 134.04 67.52 1
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Hig. 4. Predicted singly charged and doubly charged b-ions and y-ions produced b
1—BRPs  identiﬁed in both Pachymedusa dacnicolor and Agalychnis callidryas skin s
nd  are underlined.
mooth muscle preparations. Not surprisingly, the potencies of
ctions for each BRP were found to differ widely between discrete
mooth muscle preparations. In arterial smooth muscle prepara-
ions, the four BRPs from Pachymedusa dacnicolor and Agalychnis
allidryas skins (Table 1), were found to induce dose-dependent
elaxations (Fig. 7). The relative potencies were found to be
yp3-RD-11 > RD-11 > T6-BK > (Hyp3, T6)-BK. EC50 values ranged
(A)
(B)
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2
1 100.07 50.54 V 11
2 197 .12 99 .06 P 11 33.57 567 .29 10
3 294 .18 147 .59 P 10 36.52 518 .76 9
4 351 .20 176 .10 G 939 .46 470 .23 8
5 498 .27 249 .63 F 882 .44 441 .72 7
6 599 .31 300 .16 T 735 .37 368 .19 6
7 696 .37 348 .68 P 634 .33 317 .66 5
8 843 .44 422 .22 F 537 .27 269 .14 4
9 999 .54 500 .27 R 390 .20 195 .60 3
10 11 27.59 564 .30 Q 234 .10 117 .55 2
11 S 106 .04 53 .52 1
(D)
#1
1 
2 
3 
4 
5 
6 
7 
8
9 
10
11
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2
1 100 .07 50 .54 V 9
2 197 .12 99 .06 P 918 .48 459 .74 8
3 294 .18 147 .59 P 821 .43 411 .21 7
4 351 .20 176 .10 G 724 .37 362 .69 6
5 498 .27 249 .63 F 667 .35 334 .18 5
6 599 .31 300 .16 T 520 .28 260 .64 4
7 696 .37 348 .68 P 419 .24 210 .12 3
8 843 .44 422 .22 F 322 .18 161 .59 2
9 R 175 .11 88 .06 1
(C)
#1
1
2 
3 
4 
5 
6
7 
8 
9 
ig. 5. Predicted singly charged and doubly charged b-ions and y-ions produced by M
yp2-VS-11–BRPs identiﬁed in Phyllomedusa hypochondrialis skin secretion. Observed ionsMS  fragmentation of (A) Thr -BK, (B) RD-11, (C) (Hyp , T )-BK and (D) Hyp -RD-
ons. Observed ions following MS/MS fragmentation are indicated in bold-typeface
between 3.5 ± 0.3 nM and 56.7 ± 3 nM.  In contrast, the four BRPs
from Phyllomedusa hypochondrialis skin were found to be ineffec-
tive in inducing any response in this smooth muscle type up to
the maximum concentration tested of 100 M.  In urinary bladder
smooth muscle preparations (Fig. 8), the same four BRPs, found
to be active in inducing relaxation of arterial smooth muscle,
were found to contract this preparation but at signiﬁcantly lower
b(1+) b(2+) Seq. y(1+) y(2+) #2
100.07 50 .54 V 11
213.15 107 .08 P-
Oxida tion
1149.60 575 .30 10
310.21 155 .60 P 10 36.52 518 .76 9
367.23 184 .12 G 939 .46 470 .23 8
514.30 257 .65 F 882 .44 441 .72 7
615.35 308 .17 T 735 .37 368 .19 6
712.40 356 .70 P 634 .33 317 .66 5
859.47 430.23 F 537.27 269.14 4
1015.57 508 .28 R 390 .20 195 .60 3
11 43.63 572 .31 Q 234 .10 117 .55 2
 S 106 .04 53 .52 1
b(1+) b(2+) Seq. y(1+) y(2+) #2
100.07 50.54 V 9
213.15 107 .08 P-
Oxida tion
934.51 467 .76 8
310.21 155 .60 P 821 .43 411 .21 7
367.23 184 .12 G 724 .37 362 .69 6
514.30 257 .65 F 667 .35 334 .18 5
615.35 308.17 T 520.28 260.64 4
712.40 356 .70 P 419 .24 210 .12 3
859.47 430 .23 F 322 .18 161 .59 2
R 175 .11 88 .06 1
S/MS  fragmentation of (A) (V1, T6)-BK, (B) VS-11, (C) (V1, Hyp2, T6)-BK and (D)
 following MS/MS  fragmentation are indicated in bold-typeface and are underlined.
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Fig. 6. (A) Comparisons of the skin BRP-encoding domains of respective biosynthetic precursors from Agalychnis callidryas and Pachymedusa dacnicolor with those archived
from  other species of phyllomedusine frogs in the NCBI database (21 August 2013). Typical propeptide convertase sites (-KR-), located before the mature BRP regions are indi-
cated  in italics. Amino acid substitutions compared to the Agalychnis callidryas RD-11-encoding domain are indicated in bold type-face and are underlined. Database accession
numbers for indicated sequences are CCJ67651 (Agalychnis callidryas), CCJ67650 (Pachymedusa dacnicolor), AM229017 (Phyllomedusa hypochondrialis), AFR78288 (Phyllome-
dusa  bicolor), AJ549500 (Phyllomedusa sauvagei) and AM283482 (Phyllomedusa azurea). (B) Comparison of the primary structure of the Agalychnis callidryas/Pachymedusa
dacnicolor skin BRP, RD-11, with peptides exhibiting the highest degrees of sequence similarity in the NCBI database (21 August 2013). Sites of amino acid substitutions com-
pared  to RD-11, are indicated in bold type-face and are underlined. Accession numbers for Agalychnis callidryas/Pachymedusa dacnicolor are as in (A), P84824 (Ascaphus truei),
ADD13606 (Vespa tropica), Q7M3T3 (Vespa mandarinia) and P86817 (Physalaemus signifer). (C) Comparison of the skin BRP-encoding domain of the biosynthetic precursor
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-KR-),  located before the mature BRP regions are indicated in italics. Amino acid s
ndicated in bold type-face and are underlined. Database accession numbers for ind
zurea—2),  AM283481 (Phyllomedusa azurea—1) and AFY11401 (Phyllomedusa nord
otencies ranging from 895 ± 47 nM to 4.6 ± 0.5 M,  that were
anked T6-BK > RD-11 > Hyp3-RD-11 > (Hyp3, T6)-BK. In common
ith the observations from the arterial smooth muscle prepara-
ions, the four BRPs from Phyllomedusa hypochondrialis skin were
ound to be ineffective on urinary bladder smooth muscle at con-
entrations up to and including 100 M.  A similar pattern of activity
as obtained with the ﬁrst four BRPs on the smooth muscle of
he uterus but with these preparations, the effect on spontaneous
ctivity was measured by recording the dose-dependency of the
umbers of contraction peaks (Fig. 9). The rank order of potency
bserved was (Hyp3, T6)-BK > T6-BK > Hyp3-RD-11 > RD-11, with
otencies ranging from 3.9 ± 0.5 nM to 1.2 ± 0.4 M.ine frogs in the NCBI database (21 August 2013). Typical propeptide convertase sites
utions compared to the Phyllomedusa hypochondrialis VS-11-encoding domain are
 sequences are CCJ67652 (Phyllomedusa hypochondrialis), AM283483 (Phyllomedusa
.
In contrast to the strikingly different effects of the eight BRPs
on arterial, urinary bladder and uterus smooth muscle prepara-
tions, all eight were found to contract the smooth muscle of the
rat ileum (Fig. 10). EC50 values ranged between 205 ± 19 nM and
2.7 ± 0.2 M and the rank order of potency was  T6-BK > Hyp3-
RD-11 > Hyp2-VS-11 > (Hyp3, T6)-BK > VS-11 > RD-11 > (V1, Hyp2,
T6)-BK > (V1, T6)-BK. The smooth muscle pharmacology data were
complex but several broad conclusions could be made from these.
The Phyllomedusa hypochondrialis BRPs, all of which possessed a
Val (V) residue at position 1, were essentially inactive in smooth
muscle preparations from artery, urinary bladder and uterus but
displayed activity in preparations from ileum. These data are
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Fig. 7. Dose–response curves of the bradykinin like peptides (A) RD-11 (), Hyp3-
RD-11 (), VS-11 () and Hyp2-VS-11 () and (B) T6-BK (), (Hyp3, T6)-BK (), (V1,
T6)-BK () and (V1, Hyp2, T6)-BK () on rat tail arterial smooth muscle preparations
after epinephrine (10 M)  pre-contraction. Each point is plotted as a percentage
of  the maximal relaxation within its group and represents the mean ± SEM (n = 6).
The  EC50 values of RD-11 and Hyp3-RD-11 were 10.8 ± 3.3 nM and 3.5 ± 0.3 nM,
respectively. VS-11 () and Hyp2-VS-11 () were both found to be ineffective in
the  concentration range tested. The EC50 values of T6-BK and (Hyp3, T6)-BK were
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Fig. 8. Dose–response curves of the bradykinin like peptides (A) RD-11 (), Hyp3-
RD-11 (), VS-11() and Hyp2-VS-11() and (B) T6-BK (), (Hyp3, T6)-BK (),  (V1,
T6)-BK () and (V1, Hyp2, T6)-BK () on rat urinary bladder smooth muscle prepa-
rations. Each point is plotted as change in contraction strength and represents the
mean ± SEM (n = 6). The EC50 values of RD-11 and Hyp3-RD-11 were 1.1 ± 0.3 M
and  1.5 ± 0.4 M,  respectively. VS-11 () and Hyp2-VS-11 () were both found to be
6 3
RD-11 in arterial smooth muscle preparations. However, a 90-fold6.8 ± 3 nM and 56.7 ± 3 nM,  respectively. (V1, T6)-BK () and (V1, Hyp2, T6)-BK ()
ere both found to be ineffective in the concentration range tested.
uggestive either of a BK receptor with different ligand struc-
ure/activity requirements or more than one BK receptor in this
issue. Of interest, were the observations that the potency spectra
f the Phyllomedusa hypochondrialis BRPs and the common Aga-
ychnis callidryas/Pachymedusa dacnicolor BRPs, were not radically
ifferent. However, the modiﬁcations present on respective core
onapeptide sequences had different effects on relative potencies.
n the Agalychnis callidryas/Pachymedusa dacnicolor BRPs, the addi-
ion of the C-terminal dipeptide sequence, -Val-Asp (VD), to T6-BK,
esulted in a three-fold reduction in potency, whereas in contrast,
he removal of the hydroxylation at Pro2 and the removal of the
-terminal dipeptide sequence, -Gln-Ser (-QS), from Hyp2-VS-11,
esulted in a six-fold reduction in potency. The fact that the largest
iscrepancy in potency, however (13-fold), was observed between
hr6-BK and (V1, T6)-BK, might more reasonably be explained by
he presence of two BK receptors of different ligand speciﬁcity in
his tissue.In arterial smooth muscle, Hyp3-RD-11 was found to be the most
otent BRP in inducing relaxation with a sixteen-fold reduction in
otency being observed by removal of the C-terminal dipeptideineffective in the concentration range tested. The EC50 values of T -BK and (Hyp ,
T6)-BK were 895 ± 47 nM and 4.6 ± 0.5 M,  respectively. (V1, T6)-BK () and (V1,
Hyp2, T6)-BK () were both found to be ineffective in the concentration range tested.
extension sequence, -VD. Early studies that examined the arterial
vasodilatory and ensuing hypotensive effects of the phyllomedu-
sine frog BRP, phyllokinin (RPPGFSPFRIY-SO3H), found it to be more
potent than BK [7,8]. This effect was attributed to its longer plasma
half-life due to the fact that the C-terminal dipeptide extension
acted as a “foil” for angiotensin-converting enzyme (ACE) that
effectively, by removal of this sequence, generated BK that was
then subsequently inactivated by the same protease. BK, in contrast,
would be inactivated rapidly by the initial cleavage of ACE at its C-
terminus. This would effectively explain the enhanced potency of
the C-terminally extended RD-11 over the nonapeptide BK in the
vascular smooth muscle preparation used in this study. Of interest,
was the lower observed enhancing effect of Pro3 hydroxylation of
RD-11.
In uterine smooth muscle preparations, (Hyp3, T6)-BK was found
to have an almost identical potency to that observed for Hyp3-reduction in potency was observed by addition to this of the
C-terminal dipeptide, -VD, and a 300-fold reduction in potency
followed addition of -VD to the C-terminus and removal of the
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Fig. 9. Dose–response curves of the bradykinin like peptides (A) RD-11 (), Hyp3-
RD-11 (), VS-11() and Hyp2-VS-11() and (B) T6-BK (), (Hyp3, T6)-BK (), (V1,
T6)-BK () and (V1, Hyp2, T6)-BK () on rat uterus smooth muscle preparations.
Each point is plotted as the number of contraction peak changes during each 5 min
interval and represents the mean ± SEM (n = 6). The EC50 values of RD-11 and Hyp3-
RD-11 were 1.2 ± 0.4 M and 356 ± 34 nM, respectively. VS-11 () and Hyp2-VS-11
()  were both found to be ineffective in the concentration range tested. The EC50
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Fig. 10. Dose–response curves of the bradykinin like peptides (A) RD-11 (), Hyp3-
RD-11 (), VS-11 () and Hyp2-VS-11 () and (B) T6-BK (), (Hyp3, T6)-BK (), (V1,
T6)-BK () and (V1, Hyp2, T6)-BK () on rat ileum smooth muscle preparations. Each
point is plotted as change in contraction strength and represents the mean ± SEM
(n  = 6). The EC50 values for each peptide were 645 ± 12 nM (RD-11), 223 ± 14 nMalues of T6-BK and (Hyp3, T6)-BK were 60.3 ± 4.8 nM and 3.9 ± 0.5 nM,  respec-
ively. (V1, T6)-BK () and (V1, Hyp2, T6)-BK () were found to be ineffective in
he  concentration range tested.
ydroxylation on Pro3. These BRP structure/activity data would
end suggest different receptors on arterial and uterus smooth
uscles but we suggest an alternative explanation for these obser-
ations. This may  not be due to ligand speciﬁcity per se but rather
o different protease activities in each preparation. The vascular
ystem is the richest source of ACE—a fact that rendered this pro-
ease an amenable drug target for the design of antihypertensive
rugs, as inhibition of its activity could simultaneously prevent the
egradation of BK (a vasodilator) and generation of angiotensin-II
a vasoconstrictor) from angiotensin-I [13,19,21]. The vasorelaxant
ctivity of the BK nonapeptide is mediated through the B2-receptor
hat requires an intact C-terminus on the ligand for activation [15].
uriously, while this site is available on (Hyp3, T6)-BK (the most
otent uterus smooth muscle ligand), it is blocked by the exten-
ion peptide, -VD, on Hyp3-RD-11, the most potent arterial smooth
uscle ligand. However, the data could be explained by the action
f ACE, that would effectively rapidly remove the C-terminal dipep-
ide extension from Hyp3-RD-11 thus generating (Hyp3, T6)-BK.
CE may  not be expressed on the smooth muscles of the uterus and(Hyp3-RD-11), 606 ± 12 nM (VS-11), 455 ± 10 nM (Hyp2-VS-11), 205 ± 19 nM (T6-
BK),  588 ± 14 nM ((Hyp3, T6)-BK), 2.73 ± 0.2 M ((V1, T6)-BK) and 710 ± 11 nM ((V1,
Hyp2, T6)-BK).
hence this preparation responds best to the BK nonapeptide ligand.
Thus the target receptor and its ligand structure/activity require-
ments may  actually be the same in both preparations consistent
with that of a classical BK B2-receptor [15,16].
T6-BK was the most potent ligand for contraction of urinary
bladder smooth muscle but was  15- to 50-fold less potent than in
arterial and uterus smooth muscle. Unlike in these latter smooth
muscle preparations, hydroxylation of Pro3 resulted in a 5-fold
reduction rather than an enhancement of potency. In contrast to
the lack of effects observed for the Phyllomedusa hypochondrialis
BRPs (all Val1-containing peptides) in arterial, uterus and urinary
bladder smooth muscle preparations, all were found to possess
contractile activity on the ileum smooth muscle preparation at
only slightly lower potencies than their corresponding post-
translationally processed/modiﬁed Arg1-containing counterparts
from Agalychnis callidryas/Pachymedusa dacnicolor skins. These data
would be highly suggestive of common actions through a dif-
ferent receptor than that occurring in the other smooth muscle
preparations. While all eight peptides were active, possessing
ED50 values ranging between 205 ± 19 nM (T6-BK) and 2.7 ± 0.2 M
((V1, T6)-BK), the effect of the Val1 substitution was  obvious as
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Table 2
Effects of bradykinin B1 (des Arg-HOE140) and B2 (HOE140) receptor antagonists
on  inhibition of smooth muscle responses to bradykinin (BK) and the range of
phyllomedusine frog skin BRPs identiﬁed in this study. All peptides employed at
a  concentration of 10 M.  Values represent range of responses obtained with 3
preparations.
Peptide Tissue % of maximal response
Artery B1 antagonist B2 antagonist
BK 76–80 10–16
RD-11 60–76 2–5
Hyp3-RD-11 87–98 14–20
T6-BK 56–68 50–55
Hyp3, T6-BK 12–17 62–74
Bladder
BK 96–98 12–15
RD-11 48–50 70–73
Hyp3-RD-11 95–98 1–2
T6-BK 72–78 71–73
Hyp3, T6-BK 89–93 52–59
Uterus
BK 71–74 26–29
RD-11 90–97 37–40
Hyp3-RD-11 92–97 27–30
T6-BK 28–40 22–30
Hyp3, T6-BK 85–88 54–55
Ileum
BK 98–100 28–36
RD-11 20–23 1–4
Hyp3-RD-11 23–29 1–7
T6-BK 1–4 12–15
Hyp3, T6-BK 4–5 7–12
VS-11 55–65 57–59
Hyp2-VS-11 4–8 48–54
r
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[
[
[
[
[
[V1, T6-BK 4–7 20–27
V1, Hyp2, T6-BK 1–5 80–92
eﬂected in these extremes of potency data. The effect on activ-
ty of post-translational modiﬁcations, such as hydroxylation of
ither Pro2 or Pro3, and that of the C-terminal extensions, was
inimal.
While the common BRPs from Agalychnis callidryas/
achymedusa dacnicolor skins have structures that facilitate
nteractions with mammalian BK receptors that are generally
ssumed to mediate some defensive functions for the frog, it is
ssumed that the Val1-substituted BRPs, that mimic  endogenous
olubrid snake BK, have evolved to interact with the snake BK
eceptors to mediate a similar defensive function for the frog
gainst these common and established group of amphibian
redators [9].
Several interesting insights into bioactive peptide biol-
gy/pharmacology have been gained from this study. The spectrum
f BK analogs produced in amphibian defensive skin secretions is
nique in Nature and most components have not been compara-
ively evaluated alongside BK to interrogate the structure/activity
equirements of mammalian BK receptors with the view to identi-
ying novel receptors or novel receptor sub-types. The data derived
rom such comparative studies of ligand potency should be inter-
reted with caution as some analogs, particularly those with
xtensions at either N- or C-terminals, may  have radically differ-
nt values due to longer biological half-lives (as a consequence
f increased stability to protease attack) or to their requirements
or bioactivation through exposure of active, receptor-binding sites
2,9,15,17]. The studies on each smooth muscle type performed in
he absence or presence of speciﬁc bradykinin B1 and B2 receptor
ntagonists produced additional evidence to interpret the rela-
ive myotropic activities obtained in the previous dose–response
tudies. The picture, however, was complex but some general con-
lusions could be deduced. Assuming that additional subtypes of
radykinin receptor are not involved and that data obtained with
he antagonists are speciﬁc for respective established subtypes,
[
[2 (2014) 122–133
then it could be concluded that the effects observed for the major-
ity of the BRPs are mediated predominantly through B2 receptors
in artery, bladder and uterus. However, in contrast, the effects
observed for most in the ileum would suggest predominant inter-
action through a B1-type receptor although some peptides, such
as RD-11 and its Hyp3 analog, are acting predominantly through
a B2-type receptor. In some tissues, the ileum in particular, there
appears to be signiﬁcant interaction with most BRPs through both
receptors.
Thus, it is without doubt that the amphibian skin represents
the most unique natural source of an abundance of BRPs that in
turn, represent a unique resource for pharmacological exploitation
through receptor characterization and perhaps as tools for identi-
ﬁcation of novel bradykinin receptor subtypes.
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